Jun. 21 at 1:52 PM
$AIFF
Firefly's breakthrough is both scientifically impressive and strategically positioned. The path to revenue involves:
Clinics adopting BNA for objective diagnostics.
Validation through trials like Hemostemix’s.
Securing reimbursement — the true tipping point.
Scaling globally, expanding license and pharma deals.
For investors, the stock should be viewed as a high-risk, high-reward biotech/AI play. Success hinges on deliverables: clinical data, regulatory clarity, and revenue signals.
If milestones are met, a market cap in the hundreds of millions to over
$1B becomes plausible—making today’s sub-
$50M revenue base merely a starting point.